Literature DB >> 27973745

Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes.

S K Park1,2, S D Harlow1, H Zheng1,3, C Karvonen-Gutierrez1, R C Thurston4,5, K Ruppert5, I Janssen6, J F Randolph7.   

Abstract

AIM: To investigate the association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and incident diabetes.
METHODS: We followed 1407 pre-menopausal women, aged 42-52 years at baseline, who experienced natural menopause, from baseline to the 12th annual follow-up visit in the Study of Women's Health Across the Nation (SWAN). Diabetes was defined based on fasting glucose level, medication use and self-report of physician diagnosis. Cox proportional hazards regression was used to evaluate the associations of incident diabetes with three components of the rate of change in hormones: the intercept (pre-menopausal levels) and two piece-wise slopes representing change during the early and late transition, respectively.
RESULTS: During 15 years of follow-up, 132 women developed diabetes. After adjusting for potential confounders, a higher oestradiol intercept, but not its rate of change, was borderline significantly associated with lower risk of diabetes [hazard ratio for an interquartile range increase (75.2 pmol/L) 0.53, 95% CI 0.27-1.06]. For follicle-stimulating hormone, a greater rate of increase in the early transition, but not the intercept or late transition, was significantly associated with lower risk of diabetes [hazard ratio for an interquartile range increase (5.9 IU/L/year) 0.31, 95% CI 0.10-0.94].
CONCLUSIONS: Lower pre-menopausal oestradiol levels and a slower rate of follicle-stimulating hormone change during the early transition were associated with higher risk of developing diabetes. Given that obesity plays an important role in diabetes risk and in the levels and changes in oestradiol and follicle-stimulating hormone over the menopausal transition, weight control in earlier mid-life is important to prevent future diabetes development.
© 2016 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27973745      PMCID: PMC5352524          DOI: 10.1111/dme.13301

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  29 in total

1.  How estrogens prevent from lipid-induced insulin resistance.

Authors:  Tomas Jelenik; Michael Roden
Journal:  Endocrinology       Date:  2013-03       Impact factor: 4.736

2.  Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women.

Authors:  G B Phillips; C H Tuck; T Y Jing; B Boden-Albala; I F Lin; N Dahodwala; R L Sacco
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

Review 3.  Estrogen production and action.

Authors:  L R Nelson; S E Bulun
Journal:  J Am Acad Dermatol       Date:  2001-09       Impact factor: 11.527

Review 4.  Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis.

Authors:  An Pan; Yeli Wang; Mohammad Talaei; Frank B Hu; Tangchun Wu
Journal:  Lancet Diabetes Endocrinol       Date:  2015-09-18       Impact factor: 32.069

5.  The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women.

Authors:  Rita Rastogi Kalyani; Manuel Franco; Adrian S Dobs; Pamela Ouyang; Dhananjay Vaidya; Alain Bertoni; Susan M Gapstur; Sherita Hill Golden
Journal:  J Clin Endocrinol Metab       Date:  2009-09-29       Impact factor: 5.958

6.  Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial.

Authors:  Alka M Kanaya; David Herrington; Eric Vittinghoff; Feng Lin; Deborah Grady; Vera Bittner; Jane A Cauley; Elizabeth Barrett-Connor
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

7.  Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition.

Authors:  Sybil Crawford; Nanette Santoro; Gail A Laughlin; Mary Fran Sowers; Daniel McConnell; Kim Sutton-Tyrrell; Gerson Weiss; Marike Vuga; John Randolph; Bill Lasley
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

8.  Follicle stimulating hormone and its rate of change in defining menopause transition stages.

Authors:  MaryFran R Sowers; Huiyong Zheng; Daniel McConnell; Bin Nan; Sioban Harlow; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

9.  Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women.

Authors:  MaryFran R Sowers; Huiyong Zheng; Daniel McConnell; Bin Nan; Siobán D Harlow; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

10.  Testosterone concentrations in women and men with NIDDM.

Authors:  B Andersson; P Mårin; L Lissner; A Vermeulen; P Björntorp
Journal:  Diabetes Care       Date:  1994-05       Impact factor: 19.112

View more
  14 in total

Review 1.  Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications.

Authors:  Franck Mauvais-Jarvis; JoAnn E Manson; John C Stevenson; Vivian A Fonseca
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

2.  Supplementation with omega-3 or omega-6 fatty acids attenuates platelet reactivity in postmenopausal women.

Authors:  Adriana Yamaguchi; Livia Stanger; John Cody Freedman; Amanda Prieur; Rachel Thav; Jennyfer Tena; Theodore R Holman; Michael Holinstat
Journal:  Clin Transl Sci       Date:  2022-07-25       Impact factor: 4.438

Review 3.  The interplay between diabetes mellitus and menopause: clinical implications.

Authors:  Irene Lambrinoudaki; Stavroula A Paschou; Eleni Armeni; Dimitrios G Goulis
Journal:  Nat Rev Endocrinol       Date:  2022-07-07       Impact factor: 47.564

4.  Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing.

Authors:  Howard N Hodis; Wendy J Mack
Journal:  Cancer J       Date:  2022 May-Jun 01       Impact factor: 2.074

5.  Estradiol (E2) Improves Glucose-Stimulated Insulin Secretion and Stabilizes GDM Progression in a Prediabetic Mouse Model.

Authors:  Moritz Liebmann; Melissa Asuaje Pfeifer; Katharina Grupe; Stephan Scherneck
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

6.  Sexual dimorphism of gut microbiota at different pubertal status.

Authors:  Xin Yuan; Ruimin Chen; Ying Zhang; Xiangquan Lin; Xiaohong Yang
Journal:  Microb Cell Fact       Date:  2020-07-28       Impact factor: 5.328

7.  Investigation of Comorbidity, Trauma History, and Osteoporotic Fractures in the Postmenopausal Population: A Nationwide, Observational, and Cross-Sectional Study of Korean Orthopedic Outpatient Clinics.

Authors:  Minjoon Cho; Seoung-Hwan Moon; Ji-Ho Lee; Jae Hyup Lee
Journal:  Asian Spine J       Date:  2019-05-14

8.  Aging Reduces Estradiol Protection Against Neural but Not Metabolic Effects of Obesity in Female 3xTg-AD Mice.

Authors:  Amy Christensen; Jiahui Liu; Christian J Pike
Journal:  Front Aging Neurosci       Date:  2020-05-05       Impact factor: 5.750

9.  Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update.

Authors:  Stavroula A Paschou; Nikolaos Papanas
Journal:  Diabetes Ther       Date:  2019-09-24       Impact factor: 2.945

10.  Ovariectomy Impaired Hepatic Glucose and Lipid Homeostasis and Altered the Gut Microbiota in Mice With Different Diets.

Authors:  Zili Lei; Huijuan Wu; Yanhong Yang; Qing Hu; Yuting Lei; Wanwan Liu; Ya Nie; Lanxiang Yang; Xueying Zhang; Changyuan Yang; Ting Lin; Fengxue Tong; Jiamin Zhu; Jiao Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-30       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.